أعرض في EDS

85. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy

التفاصيل البيبلوغرافية
العنوان: 85. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
المؤلفون: Tim Gathany, Stephen Xu, Mittie K. Doyle, Josef S. Smolen, Elizabeth C. Hsia, Jürgen Wollenhaupt, Robert Landewé, Yiying Zhou, Jonathan Kay, Chenglong Han, Frederick T. Murphy, Norman Gaylis, Eric Matteson
المصدر: Rheumatology. 53:i87-i88
بيانات النشر: Oxford University Press (OUP), 2014.
سنة النشر: 2014
مصطلحات موضوعية: medicine.medical_specialty, business.industry, Placebo-controlled study, medicine.disease, Gastroenterology, Golimumab, Anti-Tumor Necrosis Factor Therapy, Rheumatology, Rheumatoid arthritis, Internal medicine, medicine, Pharmacology (medical), In patient, business, medicine.drug
تدمد: 1462-0332
1462-0324
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::89c0b8cb4abddca6cf16e1c198ec8d4e
https://doi.org/10.1093/rheumatology/keu101.006
حقوق: OPEN
رقم الأكسشن: edsair.doi...........89c0b8cb4abddca6cf16e1c198ec8d4e
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14620332
14620324